S. Orimo, E. Ozawa, S. Nakade, T. Sugimoto, and H. Mizusawa, )Imetaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease, J Neurol Neurosurg Psychiatr, vol.67, issue.123, pp.189-94, 1999.

H. Takatsu, H. Nishida, H. Matsuo, S. Watanabe, K. Nagashima et al., Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG, J Nucl Med, vol.41, pp.71-78, 2000.

T. Amino, S. Orimo, Y. Itoh, A. Takahashi, T. Uchihara et al., Profound cardiac sympathetic denervation occurs in Parkinson disease, Brain Pathol, vol.15, pp.29-34, 2005.

S. Orimo, T. Amino, T. Uchihara, F. Mori, A. Kakita et al., Decreased cardiac uptake of MIBG is a potential biomarker for the presence of Lewy bodies, J Neurol, vol.254, pp.21-29, 2007.

J. Spiegel, diagnostic and pathophysiological impact of myocardial MIBG scintigraphy in parkinson's disease, Parkinsons Dis, 2010.

A. E. King, J. Mintz, and D. R. Royall, Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders, Mov Disord, vol.26, pp.1218-1242, 2011.

G. Treglia, E. Cason, A. Stefanelli, F. Cocciolillo, D. Giuda et al., MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis, Clin Auton Res, vol.22, pp.43-55, 2012.

S. Orimo, M. Suzuki, A. Inaba, and H. Mizusawa, 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis, Parkinsonism Relat Disord, vol.18, pp.494-500, 2012.

A. Flotats, I. Carrió, D. Agostini, L. Guludec, D. Marcassa et al., Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology, Eur J Nucl Med Mol Imaging, vol.37, pp.1802-1814, 2010.

A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatr, vol.55, pp.181-185, 1992.

I. G. Mckeith, D. W. Dickson, J. Lowe, M. Emre, J. T. O'brien et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, vol.65, pp.1863-72, 2005.

S. Gilman, G. K. Wenning, P. A. Low, D. J. Brooks, C. J. Mathias et al., Second consensus statement on the diagnosis of multiple system atrophy, Neurology, vol.71, pp.670-676, 2008.

I. Litvan, Y. Agid, D. Calne, G. Campbell, B. Dubois et al., Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop, Neurology, vol.47, pp.1-9, 1996.

M. J. Armstrong, I. Litvan, A. E. Lang, T. H. Bak, K. P. Bhatia et al., Criteria for the diagnosis of corticobasal degeneration, Neurology, vol.80, pp.496-503, 2013.

A. Stefanelli, G. Treglia, I. Bruno, V. Rufini, and A. Giordano, Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?, Eur Rev Med Pharmacol Sci, vol.17, pp.1326-1359, 2013.

I. Carrió, Cardiac Neurotransmission Imaging*, J Nucl Med, vol.42, pp.1062-76, 2001.

A. Muxí, P. Paredes, I. Navales, F. Valldeoriola, C. Gaig et al., Diagnostic cutoff points for 123 I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson's disease, Eur J Nucl Med Mol Imaging, vol.38, pp.1139-1185, 2011.

M. Suzuki, A. Kurita, M. Hashimoto, N. Fukumitsu, M. Abo et al., Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease, J Neurol Sci, vol.240, pp.15-24, 2006.

J. Spiegel, D. Hellwig, G. Farmakis, W. H. Jost, S. Samnick et al., Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease, Mov Disord, vol.22, pp.1004-1012, 2007.

E. J. Chung, E. G. Kim, M. S. Kim, S. K. Bae, D. H. Seog et al., Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson's disease, J Clin Neurosci, vol.18, pp.922-927, 2011.

A. Chiaravalloti, A. Stefani, M. Tavolozza, M. Pierantozzi, D. Biagio et al., Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with 123

I. , Mol Med Rep, vol.6, pp.1337-1379, 2012.

J. Kim, Y. Shim, I. Song, J. Yoo, H. Kim et al., Cardiac sympathetic denervation and its association with cognitive deficits in Parkinson's disease, Parkinsonism Relat Disord, vol.15, pp.706-714, 2009.

D. M. Raffel, R. A. Koeppe, R. Little, C. Wang, S. Liu et al., PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes, J Nucl Med, vol.47, pp.1769-77, 2006.

J. Spiegel, D. Hellwig, W. H. Jost, G. Farmakis, S. Samnick et al., Cerebral and extracranial neurodegeneration are strongly coupled in PArkinson's disease, Open Neurol J, vol.1, pp.1-4, 2007.

K. Ishibashi, Y. Saito, S. Murayama, K. Kanemaru, K. Oda et al., Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET, Eur J Nucl Med Mol Imaging, vol.37, pp.3-11, 2010.

H. Sawada, T. Oeda, K. Yamamoto, N. Kitagawa, E. Mizuta et al., Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease, Eur J Neurol, vol.16, pp.174-82, 2009.